Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01079936 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and High-Dose Melphalan
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT01079936: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01079936 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01079936, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of Revlimid (lenalidomide) and high-dose Alkeran (melphalan) that can be given to patients with multiple myeloma who will receive an autologous stem cell transplantation. The safety of this combination therapy will also be studied.
Interventions
- DRUG Melphalan
- DRUG Lenalidomide
- PROCEDURE Stem Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01079936
The ClinicalTrials.gov registry entry for NCT01079936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Melphalan is the first listed.
NCT01079936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01079936 about?
NCT01079936 is a clinical study titled "Lenalidomide and High-Dose Melphalan". The goal of this clinical research study is to find the highest tolerable dose of the combination of Revlimid (lenalidomide) and high-dose Alkeran (melphalan) that can be given to patients with multiple myeloma who will receive an autologous stem cell transplantation. The safety of this combination ...
What is the current status of trial NCT01079936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2010-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01079936?
The interventions under investigation include: Melphalan (DRUG), Lenalidomide (DRUG), Stem Cell Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT01079936?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.